Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-20
DOI
10.1186/s12933-020-01073-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats
- (2019) Poonam Giri et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype
- (2019) Daisuke Mori et al. Cardiovascular Diabetology
- New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
- (2019) Upendra Kaul et al. Cardiovascular Diabetology
- Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case–control study
- (2019) Min-Hee Woo et al. Cardiovascular Diabetology
- Saroglitazar Reduces Predictor Lipid Biomarkers Of Cardiovascular Diseases
- (2019) M. Krishnappa et al. ATHEROSCLEROSIS
- Efficacy and Safety of Saroglitazar in Nonalcoholic Fatty Liver Disease Patients at 1 Year: An Investigator Initiated Study
- (2019) Sunil K. Dadhich AMERICAN JOURNAL OF GASTROENTEROLOGY
- Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study
- (2018) Cheng-Wei Chan et al. Cardiovascular Diabetology
- Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue
- (2018) Durgesh Kumar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
- (2017) Yan Zheng et al. Nature Reviews Endocrinology
- Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial
- (2016) A. O. Stirban et al. DIABETES OBESITY & METABOLISM
- Saroglitazar for the treatment of dyslipidemia in diabetic patients
- (2015) Shashank R Joshi EXPERT OPINION ON PHARMACOTHERAPY
- Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
- (2015) Sosale Aravind Sosale et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The First Approved Agent in the Glitazar’s Class: Saroglitazar
- (2014) Ritesh Agrawal CURRENT DRUG TARGETS
- Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus
- (2014) A. Michael Lincoff et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The long and winding road to optimal HbA1c measurement
- (2013) Randie R. Little et al. CLINICA CHIMICA ACTA
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
- (2013) Rajendrakumar H. Jani et al. Diabetes Technology & Therapeutics
- Genome-Wide Association Study for Type 2 Diabetes in Indians Identifies a New Susceptibility Locus at 2q21
- (2012) R. Tabassum et al. DIABETES
- Does Aggressive Glycemic Control Benefit Macrovascular and Microvascular Disease in Type 2 Diabetes?: Insights from ACCORD, ADVANCE, and VADT
- (2011) Toni Terry et al. Current Cardiology Reports
- PPAR-γ Agonists and Their Role in Type 2 Diabetes Mellitus Management
- (2010) Valmore Bermúdez et al. AMERICAN JOURNAL OF THERAPEUTICS
- Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
- (2009) Robert R Henry et al. LANCET
- Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
- (2009) Giuseppe Derosa et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations
- (2008) Hiroyuki Unoki et al. NATURE GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More